Luye Pharma Group Ltd.
LYPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $7,221,355 | $9,436,518 | $10,116,452 | $11,433,708 |
| - Cash | $6,936,206 | $4,937,145 | $3,339,649 | $5,654,804 |
| + Debt | $11,870,636 | $10,321,054 | $9,453,292 | $8,423,947 |
| Enterprise Value | $12,155,785 | $14,820,427 | $16,230,095 | $14,202,851 |
| Revenue | $3,181,110 | $2,986,859 | $3,074,582 | $3,238,970 |
| % Growth | 6.5% | -2.9% | -5.1% | – |
| Gross Profit | $2,157,609 | $1,965,677 | $2,078,550 | $2,260,812 |
| % Margin | 67.8% | 65.8% | 67.6% | 69.8% |
| EBITDA | $1,003,569 | $1,252,206 | $939,470 | $1,028,627 |
| % Margin | 31.5% | 41.9% | 30.6% | 31.8% |
| Net Income | $312,886 | $84,050 | $387,836 | $382,628 |
| % Margin | 9.8% | 2.8% | 12.6% | 11.8% |
| EPS Diluted | 0.083 | -0.083 | 0.1 | 0.102 |
| % Growth | 200.8% | -182.5% | -1.8% | – |
| Operating Cash Flow | $1,784,352 | $562,164 | -$394,400 | $905,760 |
| Capital Expenditures | $0 | -$1,708,497 | $0 | -$632,656 |
| Free Cash Flow | $1,784,352 | -$1,146,333 | -$394,400 | $273,104 |